Pfizer Canada and BioNTech receive Health Canada approval of LP.8.1 variant adapted COMIRNATY COVID-19 vaccine for individuals aged 6 months and older ($25.07, 0.00)
Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine
HHS revives task force on safer childhood vaccines
FDA reportedly considering ending authorization of Pfizer's Covid vaccine in children aged under 5 -- Bloomberg ($24.58, 0.00)
Follow-up: GSK PLC to tender its ~16.6M CureVac shares in BioNTech offer ($5.46, 0.00)
GSK PLC notes CureVac/BioNTech mRNA patent litigation settlement; will receive $370M upfront and 1% royalty in respect of US sales of influenza, COVID-19 and related combination mRNA vaccine products by BioNTech and Pfizer (1383.0000p, 0)
CureVac announces GSK, BioNTech and Pfizer have entered into agreements to resolve and dismiss all pending patent litigation in the U.S. between the companies related to mRNA-based COVID-19 vaccines ($5.46, 0.00)
StreetAccount Sector Summary - Healthcare Post-Market
StreetAccount Summary - US Pre-market trading update
Powered by FactSet Research Systems Inc.